PLUR — Pluri Inc.

Nasdaq · Health Care · Biotechnology · CIK 1158780 · Israel
Last close
$2.31
Market Cap
$24.92M
52W High
$3.89
52W Low
$2.22
ADV30
11,288
Next earnings
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 167,000 56,000 -6,536,000 -5,548,000 26,057,000 3,419,000 39,056,000
Dec 2025 198,000 86,000 -6,506,000 -6,543,000 30,596,000 4,690,000 39,809,000
Sep 2025 316,000 115,000 -6,350,000 -5,850,000 33,672,000 4,259,000 39,319,000
Jun 2025 398,000 207,000 -6,621,000 -7,598,000 38,683,000 5,895,000 39,548,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,152,000
Investing CF
$5,304,000
Financing CF
$9,533,000
CapEx
$-1,861,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.83
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-455,448,000
Inventory
Receivables
$169,000
ST Investments
$7,792,000
EBIT TTM
$-26,224,000
Pretax Income TTM
$-27,129,000
Interest Exp TTM
$905,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,079,000
EBITDA
$-25,515,000
Free Cash Flow
$-16,613,375
Enterprise Value
$55,953,384
Total Cash
$9,322,000
Total Debt
$34,057,000
Shares Out
10,789,546
Trailing EPS
$-2.90
Book Value
$-1.78
ROE
ROA
-51.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 1,336,000 -22,176,000 -22,583,000 38,683,000 39,548,000 -18,211,000
Jun 2024 326,000 -22,158,000 -20,888,000 39,527,000 34,112,000 -18,021,000
Jun 2023 287,000 -27,246,000 -28,321,000 50,797,000 35,497,000 -22,857,000
Jun 2022 234,000 -41,593,000 -41,242,000 68,065,000 35,879,000 -36,501,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.90

Peers — same industry

TickerNameMarket CapLastDaily %
JSPR Jasper Therapeutics, Inc. $25.55M $0.91
QNCX Quince Therapeutics, Inc. $23.47M $1.20
DYAI DYADIC INTERNATIONAL INC $27.51M $0.75
CVM CEL SCI CORP $20.73M $1.43
SNTI Senti Biosciences, Inc. $30.90M $0.99

News headlines (Yahoo Finance, 1h cache)

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
2026-03-26 12:30 · Yahoo
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
2026-02-18 13:00 · Yahoo
Pluri: Fiscal Q2 Earnings Snapshot
2026-02-12 22:12 · Yahoo
Pluri showcases cell expansion platform as Resbiomed program advances
2026-02-09 15:30 · Yahoo
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
2026-01-22 14:15 · Yahoo
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
2025-12-22 12:00 · Yahoo
A US$3.4m Market Cap Boost Pleasing ToPluri Insiders
2025-12-19 10:38 · Yahoo
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
2025-12-09 13:30 · Yahoo
Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
2025-11-13 13:00 · Yahoo
Pluri: Fiscal Q1 Earnings Snapshot
2025-11-12 21:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.